Skip to main content

2 Top Trends to Invest $2,000 in Ahead of the Crowd – The Motley Fool

There’s an old chestnut that most investors could stand to hear: If you want to succeed in investing (or hockey), skate to where the puck is going, not to where it’s been.

Buying shares of yesterday’s winning businesses might be a decent way to preserve your wealth by banking on their continued success, but if you want to nab big gains, you’ll need to invest in companies that are working on solving tomorrow’s problems today. Clocking important trends in the economy and the world is critical for guiding your search.

So let’s take a look at two trends that’ll likely be huge in the near future. You’ll gain a few actionable ideas about investments that could pay off down the line.

1. Psychedelic therapies for mental illnesses

Psychedelic drugs like psilocybin, LSD, ketamine, and MDMA aren’t legal to use recreationally in most places, but that doesn’t mean they can’t be powerful medicines when used appropriately.

The current standards of care for some common yet difficult-to-treat conditions like major depressive disorder are interventions like antidepressant drugs and cognitive behavioral therapy that leave many patients experiencing relapses despite treatment. But psychedelic therapies delivered by experienced therapists might not have that problem — which could be an opportunity the businesses that make them.

Compass Pathways (CMPS 4.16%) and Atai Life Sciences (ATAI -0.68%) are two biotech stocks with pipelines chock-full of psychedelic therapies in clinical development. Per Compass’ data from one of its phase 2b studies, its COMP360 psilocybin-with-talk-therapy combination leads to rapid reduction in depression symptoms that lasts for at least 12 weeks and causes few serious side effects. For some subsets of patients, the improvements appear to be long-lasting or perhaps even permanent. And Atai’s equity interest in Compass means that it stands to benefit from the therapy’s sales if it’s eventually commercialized.

But Compass’ impressive results are far from the only success story in recent clinical trials of psychedelics. Numerous third-party researchers and academic groups have shown compelling results that suggest psychedelics have the chance to reshape psychiatry as we know it, and for the better. If you want to get exposure to upside from drug development in the psychedelics space, either Atai or Compass is a suitable place to consider investing.

2. Treating or curing long COVID

As you may have heard, long COVID is an illness that features a sometimes-debilitating constellation of symptoms like fatigue, shortness of breath, and cognitive issues, all of which can occur after someone is infected with the coronavirus.

According to the Centers for Disease Control (CDC), 7.5% of adults in the U.S. are afflicted with long COVID. And an estimated 80% of people who have been infected with the coronavirus have at least one long-term symptom associated with their illness. Right now, it appears that even fully vaccinated and boosted people can experience long COVID, and even mild coronavirus infections can cause it.

To make matters worse, there are no specific treatments for it yet, and the ranks of the afflicted are, unfortunately, growing.

A few different companies are either considering or have already initiated investigations into long COVID therapies. Pfizer‘s (PFE -1.99%) antiviral medicine, Paxlovid, might soon be tested for that purpose, though no trials are currently ongoing. GlaxoSmithKline and other major drug manufacturers are also considering initiating new therapy programs, and a few biotechs have already tested candidates in clinical trials and struck out.

With so many millions of people suffering with long COVID, any medicines that successfully treat it will likely be big moneymakers. For now, there aren’t too many places to park $2,000, but if a player like Pfizer announces that it’s initiating a project, it’ll be a green light for investors. Just keep in mind that there’s a significant risk of failure in the clinical trial process, so it might make sense to pick a few different long COVID stocks to buy rather than just one.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends COMPASS Pathways plc. The Motley Fool recommends GSK plc. The Motley Fool has a disclosure policy.

Techyrack Website stock market day trading and youtube monetization and adsense Approval

Adsense Arbitrage website traffic Get Adsense Approval Google Adsense Earnings Traffic Arbitrage YouTube Monetization YouTube Monetization, Watchtime and Subscribers Ready Monetized Autoblog



from Investing – My Blog https://ift.tt/fZsIFV1
via IFTTT
Labels:

Comments

Post a Comment

Popular posts from this blog

These money and investing tips can give you a smooth ride in a rough market – MarketWatch

Don’t miss these top money and investing features: Sign up here  to get MarketWatch’s best mutual funds and ETF stories emailed to you weekly! INVESTING NEWS & TRENDS How to approach rebalancing your portfolio for 2023 It’s not a good idea to rebalance your portfolio at preset intervals Read More Bonds aren’t more attractive than stocks even as yields register a 15-year high The S&P 500’s return is similar when the 10-year Treasury yield is high or low. Read More Here’s who’s been trading crypto, and how they’re doing A new study finds that most people who entered the cryptocurrency market have lost money — and that those people are young men. Read More BlackRock sees these thematic ETFs potentially outperforming in 2023 In this week’s ETF Wrap, MarketWatch spoke with BlackRock’s Jay Jacobs on investing themes he likes for 2023 as investors worry about a slowing economy and monetary tightening. Read More Three seasonal effects in the stock market begin around T...
Post a Comment
Read more

Four months until SACSCOC visits Auburn: Four things you might not know about SACSCOC – Office of Communications and Marketing

Notice body There’s less than four months remaining until Auburn University’s accrediting body, the Southern Association of Colleges and Schools Commission on Colleges, or SACSCOC, arrives for its on-site visit. As the Accreditation team prepares for the on-site phase of the reaffirmation process, we want to share four things you might not know about SACSCOC: 1. SACSCOC is self-governed by the accredited institutions SACSCOC’s Principles of Accreditation requires a model of shared governance of its member institutions and holds itself to the same standards. The Commission on Colleges is operated by the SACSCOC Board of Trustees. The 77 Board members are elected by the College Delegate Assembly, or CDA, which is comprised of one voting representative from each of the 780 SACSCOC-accredited institutions. Each representative is the president or other chief executive of their respective college or university. In other words, the election of SACSSCOC’s leadership is in the hands of its ...
Post a Comment
Read more

5 YouTube features to use to boost engagement – Sprout Social

When you want to explore a new hobby or learn something new, where do you go? The answer is probably “YouTube.” The second-most popular social platform has come a long way since the “Charlie bit my finger” days. And new YouTube features are making it even more beneficial to marketers and creators—YouTube Shorts topped 1.5 billion monthly users in just two years. With 51% of consumers anticipating YouTube will be one of the social media platforms they use most this year, it’s a digital space your audience most likely uses. But with 500+ hours of content uploaded to YouTube every minute, high popularity also means high competition. Whether you’re new to YouTube or conducting a YouTube audit , using some of these features can help you stay ahead, grow your audience and give your channels a boost. 5 free YouTube features you need to use more often To help your audience find your videos in YouTube and Google search alike, you need to use the right tools. From underused YouTube sear...
Post a Comment
Read more